The influence of HER2 genotypes as molecular markers in ovarian cancer outcome

• Tipo: Artigo em Revista Científica Internacional
• Data: 2005

Autores

Pinto, D (Autor) Outra; Pereira, D (Autor) Outra; Portela, C (Autor) Outra; da Silva, JL (Autor) Outra; Carlos, LA (Autor) Outra; Medeiros, R (Autor) ICBAS

Revista

Título: Biochemical and Biophysical Research Communications

Vol. 335

Páginas: 1173-1178

ISSN: 0006-291X

Editora: Elsevier

Indexação

ISI Web of Knowledge - 29 Citações

Scopus - 29 Citações

Classificação Científica

FOS: Ciências exactas e naturais > Ciências biológicas

Outras Informações

ID Authenticus: P-000-0YF

DOI: 10.1016/j.bbrc.2005.08.012

Abstract (EN): A relevant clinical problem in the treatment of ovarian cancer (OC) is the development of resistance to chemotherapy, frequently due to genetic variations in enzymes and receptors. Changes in the HER2 receptor have been associated with breast and ovarian cancers. The role of a polymorphism in the HER2 gene in the clinical outcome of OC patients was investigated in this study. We characterized DNA samples from 111 patients with OC treated with cisplatin and paclitaxel, using PCR-RFLP. Our results indicate that patients carrying the valine homozygotic genotype present a lower overall survival mean, suggesting a role for this polymorphism in the outcome of ovarian cancer patients. The G allele has been implicated in the formation of active HER2 receptors, with a more aggressive phenotype. We hypothesize that HER2 genotypes can be predictive biomarkers in ovarian cancer, contributing to a genetic individual profile of great interest in clinical oncology.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 6